The estimated Net Worth of Dwight Moxie is at least $3.23 Million dollars as of 15 March 2024. Mr. Moxie owns over 8,125 units of Revance Therapeutics Inc stock worth over $906,823 and over the last 5 years he sold RVNC stock worth over $2,325,379. In addition, he makes $0 as Senior Vice President, General Counsel, and Corporate Secretary at Revance Therapeutics Inc.
Sign up
Mr. Moxie RVNC stock SEC Form 4 insiders trading
Dwight has made over 6 trades of the Revance Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 8,125 units of RVNC stock worth $40,950 on 15 March 2024.
The largest trade he's ever made was selling 34,853 units of Revance Therapeutics Inc stock on 5 September 2023 worth over $612,716. On average, Dwight trades about 5,621 units every 53 days since 2020. As of 15 March 2024 he still owns at least 137,815 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Moxie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dwight Moxie biography
Dwight Moxie serves as Senior Vice President, General Counsel, Corporate Secretary of the Company. From January 2017 to January 2020, Mr. Moxie served as the Chief Counsel World Wide R&D, Commercial Operations, European Operations at Ultragenyx Pharmaceutical Inc., a biotechnology company, where he oversaw commercial operations, litigation, research & development and regulatory matters. From September 2011 to December 2016, Mr. Moxie served as the Chief Counsel to Eye-Care Division at Allergan plc. Mr. Moxie received a J.D. from Howard University School of Law and a B.A. from the Florida State University.
How old is Dwight Moxie?
Dwight Moxie is 44, he's been the Senior Vice President, General Counsel, and Corporate Secretary of Revance Therapeutics Inc since 2020. There are 13 older and 2 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
What's Dwight Moxie's mailing address?
Dwight's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, and Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Mr. Moxie stock trades at Revance Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director